KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Amneal Pharmaceuticals (AMRX) Shares Outstanding (Weighted Average) (2017 - 2025)

Historic Shares Outstanding (Weighted Average) for Amneal Pharmaceuticals (AMRX) over the last 9 years, with Q3 2025 value amounting to $314.2 million.

  • Amneal Pharmaceuticals' Shares Outstanding (Weighted Average) rose 146.0% to $314.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $314.2 million, marking a year-over-year increase of 146.0%. This contributed to the annual value of $309.0 million for FY2024, which is 7542.01% up from last year.
  • As of Q3 2025, Amneal Pharmaceuticals' Shares Outstanding (Weighted Average) stood at $314.2 million, which was up 146.0% from $313.7 million recorded in Q2 2025.
  • Amneal Pharmaceuticals' Shares Outstanding (Weighted Average)'s 5-year high stood at $314.2 million during Q3 2025, with a 5-year trough of $148.0 million in Q1 2021.
  • Its 5-year average for Shares Outstanding (Weighted Average) is $214.4 million, with a median of $154.0 million in 2023.
  • Its Shares Outstanding (Weighted Average) has fluctuated over the past 5 years, first surged by 56.6% in 2021, then surged by 10201.24% in 2024.
  • Over the past 5 years, Amneal Pharmaceuticals' Shares Outstanding (Weighted Average) (Quarter) stood at $149.3 million in 2021, then grew by 1.11% to $150.9 million in 2022, then increased by 16.69% to $176.1 million in 2023, then skyrocketed by 75.42% to $309.0 million in 2024, then rose by 1.68% to $314.2 million in 2025.
  • Its last three reported values are $314.2 million in Q3 2025, $313.7 million for Q2 2025, and $311.1 million during Q1 2025.